These TCL1-tg transgenic mice express the human T-cell leukemia/lymphoma 1 (TCL1) gene under the control of the mouse CD79B antigen ( Cd79b) minimal promoter. The transgene is expressed in lymphoid (B and T cell) lineage cells and precursors only. The promoter is designed to drive similar levels of expression in B and T cells. Mice hemizygous for the transgene develop mainly mature B cell lymphomas including Burkitt-like lymphoma and diffuse large B cell lymphoma. Occasional chronic B and T lymphocytic leukemias and marginal zone lymphomas also form in these mice. Most mice become clinically (visibly) ill between seven and 13 months, a few as early as four months of age. Mice that are hemizygous for the transgene are viable, normal in size and do not display any gross physical or behavioral abnormalities. Homozygotes are not viable. This mutant mouse strain may be useful in studies of mature B and T cell leukemias and lymphomas.

These TCL1-tg transgenic mice express the human T-cell leukemia/lymphoma 1 (TCL1) gene under the control of the mouse CD79B antigen ( Cd79b) minimal promoter. Mice hemizygous for the transgene develop the mature B cell lymphomas: Burkitt-like lymphoma and diffuse large B cell lymphoma. This mutant mouse strain may be useful in studies of mature B and T cell leukemias and lymphomas.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.